Why the study?
Does baseline thiol/disulfide state predict the occurrence of anthracycline-induced cardiac toxicity (decrease in LVEF) in cancer patients receiving doxorubicin-based chemotherapy?
Does baseline thiol/disulfide state predict the occurrence of anthracycline-induced cardiac toxicity (decrease in LVEF) in cancer patients receiving doxorubicin-based chemotherapy?
Baseline thiol/disulfide homeostasis markers are strong predictors of anthracycline-induced cardiac toxicity, offering a potential novel tool for early risk stratification in cardio-oncology.
The aim of the present study was to evaluate whether the baseline thiol/disulfide state can predict the occurrence of anthracycline induced cardiac toxicity. A total of 186 cancer patients receiving anthracycline (doxorubicin)-based chemotherapy were enrolled. All patients underwent 2-dimensional (2D) speckle tracking echocardiography (STE) to determine their left ventricular ejection fraction (LVEF) and blood samples for measuring thiol forms were obtained before treatment and 4 weeks after completion of the chemotherapy. The mean dose of doxorubicin exposure was 255 ± 39.2 mg/m2. Baseline native thiol was found to be lower whereas baseline disulfide and the disulfide/total thiol ratio were found to be higher in patients who had a decrease in LVEF after anthracycline therapy. Also, the amount of decrease in LVEF was well correlated with the delta value of the thiol forms. Logistic regression analysis revealed that changes in BNP and global longitudinal strain (GLS), baseline level of native thiol, disulfide, and the disulfide/total thiol ratio were strong predictors for a decrease in LVEF.
No takes yet. Share an insight, caveat, or question.
Topuz et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: